Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.

Fabrizi F, Dixit V, Messa P.

J Med Virol. 2013 Jun;85(6):1019-27. doi: 10.1002/jmv.23562.

PMID:
23588727
2.

Interferon mono-therapy for symptomatic HCV-associated mixed cryoglobulinemia : meta-analysis of clinical studies.

Fabrizi F, Dixit V, Messa P.

Acta Gastroenterol Belg. 2013 Dec;76(4):363-71. Review.

PMID:
24592538
3.

Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.

Francesca Donato M, Banfi G, Cresseri D, Battista Fogazzi G, Martin P, Messa P, Fabrizi F.

Int J Artif Organs. 2013 May 17;36(5):367-72. doi: 10.5301/ijao.5000199. Epub 2013 Feb 28. Review.

PMID:
23446762
4.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
5.

Aminoadamantanes for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 May 3;(5):CD010125. doi: 10.1002/14651858.CD010125.pub2. Review.

PMID:
24793264
6.

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.

Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P.

Drugs. 2013 Mar;73(3):263-77. doi: 10.1007/s40265-013-0027-1. Review.

PMID:
23436591
7.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

8.

Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.

Donato MF, Fabrizi F, Fogazzi GB, Cresseri D, Passerini P, Martin P, Messa P.

Int J Artif Organs. 2013 Jan;36(1):63-8. doi: 10.5301/ijao.5000166. Review.

PMID:
23280083
9.

L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.

Cacoub P, Terrier B, Saadoun D.

Presse Med. 2013 Apr;42(4 Pt 2):523-7. doi: 10.1016/j.lpm.2013.01.011. Epub 2013 Feb 28. Review. No abstract available.

PMID:
23453499
10.
11.

Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.

Saadoun D, Delluc A, Piette JC, Cacoub P.

Curr Opin Rheumatol. 2008 Jan;20(1):23-8. doi: 10.1097/BOR.0b013e3282f1330c. Review.

PMID:
18281853
12.

Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.

Li LF, Shi KQ, Lin YQ, Wang LR, He JP, Braddock M, Chen YP, Zheng MH.

Gene. 2014 Jul 10;544(2):101-6. doi: 10.1016/j.gene.2014.04.072. Epub 2014 May 1. Review.

PMID:
24793583
13.

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.

Clin Ther. 2010 Aug;32(9):1565-77. doi: 10.1016/j.clinthera.2010.08.009. Review.

PMID:
20974315
14.

Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.

Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB.

Am J Kidney Dis. 2008 Feb;51(2):263-77. doi: 10.1053/j.ajkd.2007.11.003. Review.

PMID:
18215704
15.

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.

Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P.

Liver Int. 2010 Oct;30(9):1259-69. doi: 10.1111/j.1478-3231.2010.02283.x. Review.

16.

Pegylated Interferon Mono-Therapy of Chronic Hepatitis C in the Dialysis Population: Systematic Review and Meta-Analysis.

Fabrizi F, Dixit V, Messa P, Martin P.

Ther Apher Dial. 2015 Dec;19(6):611-21. doi: 10.1111/1744-9987.12318. Epub 2015 Jul 21. Review.

PMID:
26197927
17.

Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.

Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, Atzeni F, Saccardo F, Quartuccio L, Bruno S, Bruno R, Campanini M, Candela M, Castelnovo L, Gabrielli A, Gaeta GB, Marson P, Mascia MT, Mazzaro C, Mazzotta F, Meroni P, Montecucco C, Ossi E, Piccinino F, Prati D, Puoti M, Riboldi P, Riva A, Roccatello D, Sagnelli E, Scaini P, Scarpato S, Sinico R, Taliani G, Tavoni A, Bonacci E, Renoldi P, Filippini D, Sarzi-Puttini P, Ferri C, Monti G, Galli M.

Autoimmun Rev. 2011 Jun;10(8):444-54. doi: 10.1016/j.autrev.2011.01.008. Epub 2011 Feb 15. Review.

PMID:
21303705
18.
19.

Hepatitis C virus infection and glomerular disease.

Fabrizi F, Donato F, Messa P.

Minerva Urol Nefrol. 2014 Jun;66(2):139-49. Review.

PMID:
24988205
20.

How HCV has changed the approach to mixed cryoglobulinemia.

Della Rossa A, Baldini C, Tavoni A, Bombardieri S.

Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S115-23. Review.

PMID:
19646357

Supplemental Content

Support Center